SecSonar.com

Lineage Cell Therapeutics, Inc. (LCTX)

Lineage Cell Therapeutics, Inc. at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Lineage Cell Therapeutics, Inc. (LCTX) is a Biotechnology company based in US with a market capitalization of $334.1M. Revenue grew 53.2% year-over-year and free cash flow was negative at -$19.4M. This page tracks LCTX's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · 70 employees · IPO Mar 5, 1992

Valuation

Valuation & price

$1.25 · as of May 17, 2026 · -36.2% vs 52w high

—

P/E ratio

Latest-FY diluted EPS

7.50

P/B ratio

Market cap ÷ book equity

—

Dividend yield

Price — last 12 months

$1.96$1.45$0.94Jul 25Dec 25Jul 26Jul 7, 25$0.95Jul 9, 25$1.06Jul 11, 25$1.03Jul 15, 25$1.00Jul 17, 25$0.99Jul 21, 25$0.94Jul 23, 25$1.08Jul 25, 25$1.13Jul 29, 25$1.07Jul 31, 25$1.02Aug 4, 25$0.97Aug 6, 25$0.99Aug 11, 25$1.01Aug 13, 25$1.03Aug 15, 25$1.20Aug 19, 25$1.24Aug 21, 25$1.17Aug 25, 25$1.17Aug 27, 25$1.22Aug 29, 25$1.17Sep 3, 25$1.23Sep 5, 25$1.22Sep 9, 25$1.27Sep 11, 25$1.29Sep 16, 25$1.38Sep 18, 25$1.55Sep 22, 25$1.62Sep 24, 25$1.60Sep 26, 25$1.71Sep 30, 25$1.69Oct 2, 25$1.72Oct 6, 25$1.71Oct 8, 25$1.73Oct 10, 25$1.66Oct 14, 25$1.79Oct 16, 25$1.70Oct 21, 25$1.65Oct 23, 25$1.63Oct 27, 25$1.75Oct 29, 25$1.71Oct 31, 25$1.92Nov 4, 25$1.80Nov 6, 25$1.73Nov 10, 25$1.81Nov 12, 25$1.93Nov 14, 25$1.88Nov 18, 25$1.77Nov 20, 25$1.67Nov 25, 25$1.74Nov 28, 25$1.76Dec 2, 25$1.61Dec 4, 25$1.74Dec 8, 25$1.69Dec 10, 25$1.74Dec 12, 25$1.66Dec 16, 25$1.80Dec 18, 25$1.75Dec 22, 25$1.73Dec 24, 25$1.68Dec 29, 25$1.63Jan 2, 26$1.64Jan 6, 26$1.70Jan 8, 26$1.76Jan 12, 26$1.76Jan 14, 26$1.70Jan 16, 26$1.70Jan 21, 26$1.66Jan 23, 26$1.61Jan 27, 26$1.63Jan 29, 26$1.57Feb 2, 26$1.54Feb 4, 26$1.74Feb 9, 26$1.67Feb 11, 26$1.80Feb 13, 26$1.66Feb 18, 26$1.72Feb 20, 26$1.81Feb 24, 26$1.82Feb 26, 26$1.96Mar 2, 26$1.95Mar 4, 26$1.95Mar 6, 26$1.85Mar 10, 26$1.81Mar 12, 26$1.58Mar 17, 26$1.58Mar 19, 26$1.55Mar 23, 26$1.47Mar 25, 26$1.55Mar 27, 26$1.49Mar 31, 26$1.58Apr 2, 26$1.57Apr 7, 26$1.52Apr 9, 26$1.49Apr 13, 26$1.51Apr 15, 26$1.63Apr 17, 26$1.71Apr 22, 26$1.63Apr 24, 26$1.55Apr 28, 26$1.56Apr 30, 26$1.51May 4, 26$1.42May 6, 26$1.43May 8, 26$1.37May 12, 26$1.33May 14, 26$1.31May 18, 26$1.24May 20, 26$1.29May 22, 26$1.30May 28, 26$1.33Jun 1, 26$1.26Jun 3, 26$1.20Jun 5, 26$1.19Jun 9, 26$1.22Jun 11, 26$1.28Jun 15, 26$1.23Jun 17, 26$1.25Jun 22, 26$1.26Jun 24, 26$1.26Jun 26, 26$1.28Jul 2, 26$1.34
$0.9452-week range$1.96
Loading valuation history…

Fundamentals

Key fundamentals

$334.1M

Market cap

53.2%

Revenue growth (YoY)

94.2%

Gross margin

-$19.4M

Free cash flow (USD)

-$53.4M

Net debt

Net cash position

14.9%

Share dilution

1/5

Graham criteria passed

Defensive-investor screen

Healthcare

Sector

Trajectory

Long-term trends

Revenue by year

2016 → 2025

FY 2016$2.3MFY 2017$1.8MFY 2018$1.4MFY 2019$1.5MFY 2020$773.0KFY 2021$3.9MFY 2022$14.7MFY 2023$8.9MFY 2024$9.5MFY 2025$14.6M
$2.3M$14.6M

Free cash flow by year

2016 → 2025

FY 2016$-44.9MFY 2017$-31.8MFY 2018$-34.2MFY 2019$-32.4MFY 2020$-19.8MFY 2021$-23.9MFY 2022$646.0KFY 2023$-29.2MFY 2024$-23.7MFY 2025$-19.4M
-$44.9M-$19.4M

Gross margin by year

2021 → 2025

FY 202163.4%FY 202295.0%FY 202392.5%FY 202496.5%FY 202594.2%
63.4%94.2%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last report: 10-Q filed May 12, 2026

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

  • 8-K eventAnnual Meeting ResultsJun 12, 2026Filing
  • 8-K eventEarnings ReleaseMay 12, 2026Filing
  • Quarterly report10-Q FiledMay 12, 2026Filing

Questions

Frequently asked questions

What is Lineage Cell Therapeutics, Inc.'s market cap?

Lineage Cell Therapeutics, Inc. (LCTX) has a market capitalization of $334.1M.

What is LCTX's P/E ratio?

A meaningful P/E ratio is not available for LCTX — the company's latest fiscal-year earnings per share is zero, negative, or not yet cached.

What is LCTX's price-to-book (P/B) ratio?

LCTX trades at 7.50 times book value per share.

Are insiders buying LCTX stock?

SEC Form 4 filings show no open-market insider buys at Lineage Cell Therapeutics, Inc. in the last 90 days (0 sells).

Same arena

Related companies in Biotechnology

CMPX

Compass Therapeutics, Inc.

$334M

ABEO

Abeona Therapeutics Inc.

$336M

EDIT

Editas Medicine, Inc.

$331.4M

BCYC

Bicycle Therapeutics plc

$325.5M

EVMN

Evommune, Inc.

$324.9M

OABI

OmniAb, Inc.

$323.4M

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.